Transplant patients test simpler daily Anti-Rejection pill
NCT ID NCT02882828
Summary
This study tested if switching kidney or liver transplant patients from a twice-daily anti-rejection pill (Prograf) to a newer once-daily version (Envarsus) provides the same level of drug in the body. Researchers enrolled 134 adult patients who were stable on their medication to carefully measure drug levels before and after the switch. The goal was to see if the once-daily pill is just as effective at preventing organ rejection, which would make treatment more convenient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGRAFT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HP
Paris, France
-
Limoges Hospital
Limoges, 87 042, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Reims
Reims, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Tours
Tours, France
Conditions
Explore the condition pages connected to this study.